QUOTED. 18 October 2019. CJ Porter.
Executive Summary
New Orleans-based UTC Laboratories agreed to pay $41.6m to resolve alleged violations of the False Claims Act, the US Department of Justice (DOJ) announced recently. See what CJ Porter, special agent in charge with the Department of Health and Human Service Office of the Inspector General, said about it here.
You may also be interested in...
Personalized Medicine Firm Pays $42M On Kickback Allegations Tied To Genetic-Testing Registry
Louisiana-based pharmacogenetic testing company UTC Laboratories and its three principals have agreed to pay $42.6m to resolve allegations that the company violated the False Claims Act by paying kickbacks for referrals and providing tests that were not medically necessary.
New EU Approvals
The Pink Sheet's list of EU centralized approvals of new active substances has been updated to add two new products, including Ryzneuta, Evive Biotechnology's treatment for chemotherapy-induced neutropenia.
Over The Counter 2 Apr 2024: Analyzing The Spin-Out Trend In Consumer Health, With HBW’s Malcolm Spicer And Tom Gallen
In this episode, HBW Insight’s Europe and US editors bring their expertise to bear on the current the trend towards standalone OTC companies in global consumer health. We look at four major players: Haleon, which separated from GSK almost two years ago; Kenvue, soon to celebrate its first anniversary as a new company; Sanofi Consumer Healthcare, which is poised to split from its pharma parent; and Bayer, which has decided to buck the trend, holding on to its consumer health division. We discuss some of the advantages of becoming a standalone company, for example in leaning into a wider concept of self-care.